Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines Therapeutics has announced that data from its multiple dose Phase I clinical trial of tezampanel, a novel therapeutic for chronic pain, showed that the product candidate is safe and well-tolerated in normal male and female subjects.
Subscribe to our email newsletter
The Phase I double-blind, placebo-controlled trial has enrolled 30 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily subcutaneous injections of placebo or 40mg, 70mg or 100mg of tezampanel for four consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, tezampanel was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.
Neil Kurtz, president and CEO of TorreyPines, said: “This study is an important step forward in the clinical development of tezampanel. Our ability to safely deliver multiple doses of tezampanel means that we can now pursue virtually any indication that requires chronic dosing.”